ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2024
26. Oktober 2023 16:05 ET
|
ResMed Inc.
Year-over-year revenue grows 16%, operating profit up 5%, non-GAAP operating profit up 10%Expects to resume its share repurchase program during upcoming quarter Note: A webcast of ResMed’s conference...
ResMed to Report First Quarter Fiscal 2024 Earnings on October 26, 2023
05. Oktober 2023 16:05 ET
|
ResMed Inc.
SAN DIEGO, Oct. 05, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2024 on Thursday,...
ResMed Announces Participation in Upcoming Conferences
05. September 2023 16:05 ET
|
ResMed Inc.
SAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced its participation in two upcoming conferences. Mick Farrell, chief executive officer and chair of the...
ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2023
03. August 2023 16:05 ET
|
ResMed Inc.
Year-over-year revenue grows 23%, operating profit up 8%, non-GAAP operating profit up 13%Quarterly dividend increases 9% to $0.48 per share Note: A webcast of ResMed’s conference call will be...
ResMed to Report Fourth Quarter Fiscal 2023 Earnings on August 3, 2023
06. Juli 2023 16:05 ET
|
ResMed Inc.
SAN DIEGO, July 06, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2023 on...
ResMed Acquires Somnoware, a Leader in Digital Sleep and Respiratory Care Diagnostics Software
05. Juli 2023 16:05 ET
|
ResMed Inc.
Expands ResMed’s sleep management software solution, will help sleep labs and physicians more efficiently guide patients into and through diagnosis to long-term treatmentDiagnostic management platform...
PAP Adherence Lowers ER Visits 24-36% in 1 Year for People with Sleep Apnea and Heart Failure: ResMed Studies Presented at SLEEP
08. Juni 2023 09:00 ET
|
ResMed Inc.
The studies also showed 18-40% lower costs incurred from ER visits and hospitalizations after 1 year for PAP-adherent OSA patients with diastolic and systolic heart failure, respectivelyA third study...
ResMed Announces Participation in the Goldman Sachs 44th Annual Global Healthcare Conference
05. Juni 2023 16:05 ET
|
ResMed Inc.
SAN DIEGO, June 05, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Rob Douglas, president and chief operating officer, will participate in a fireside chat at the Goldman Sachs...
3 World-Renowned Sleep Apnea Experts Present New Benefits of PAP Therapies at ATS 2023
25. Mai 2023 09:00 ET
|
ResMed Inc.
France’s Jean-Louis Pépin and Germany’s Holger Woehrle presented studies in which treating OSA with CPAP lowered all-cause mortality for PAP vs. non-PAP users with OSAGermany’s Michael Arzt presented...
ResMed Appoints Michael Rider its Next Global General Counsel, Dawn Haake its First Chief Quality Officer
02. Mai 2023 16:05 ET
|
ResMed Inc.
Rider and Haake, both internal promotions, joined ResMed’s executive team on May 1Rider, currently Senior Vice President, Deputy Global General Counsel will succeed retiring Chief Administrative...